m+Medelevator.RU
← Поиск публикаций
Cell · 2026

Cell-state-specific metabolic networks govern ferroptosis versus apoptosis in small cell lung cancer.

СтатьяНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Kim Jun W, Bebber Christina M, Dai Yuqin, Bopp Sarah, Edenhofer Anna, Li Albert M, Rösner Thomas, Berning Lena, Yang Ming, Leak Logan B, Stroh Jenny, Shrestha Bindesh, Abdallah Ali T, Prymidis Dimitrios, Olivos Hernando J, Baron Maya, Nguyen Thuyen, Shue Yan Ting, Nishiga Yoko, Drainas Alexandros P, Chaikovsky Andrea C, Szylo Krystina, Li Yang, Kang Yun P, Manoj Parvathy, Villalonga Alvaro Quintanal, Rudin Charles M, DeNicola Gina M, Dixon Scott J, Frezza Christian, Ye Jiangbin, von Karstedt Silvia, Sage Julien

Аннотация

Cellular heterogeneity and plasticity are hallmarks of cancer that contribute to tumor growth and therapy resistance. Here, we investigated metabolic heterogeneity in small cell lung cancer (SCLC), an aggressive cancer type with considerable plasticity between neuroendocrine (NE) and non-NE cellular states. Through integrated transcriptomic and metabolomic analyses, we identified a universal dependency on exogenous cysteine/cystine (Cys) across all NE/non-NE SCLC cell states. Notably, NE and non-NE cells with low ASCL1 transcription factor levels underwent ferroptosis upon Cys depletion, whereas ASCL1high cells underwent apoptosis while remaining resistant to ferroptosis. This ferroptosis resistance was driven by the direct transcriptional activation of GCH1 by ASCL1, resulting in increased levels of the antioxidants BH4/BH2. Accordingly, combined Cys depletion and inhibition of BH4/BH2 synthesis reduced tumor growth in patient-derived xenografts. These findings demonstrate that metabolic state influences cell-death susceptibility in SCLC and provide a rationale for therapeutic strategies that exploit these metabolic differences.